+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06232096

Phase 12 Study of MBS314 Injection to Assess Safety and Effectiveness in Adults with Relapsed or Refractory Multiple Myeloma

Led by Beijing Mabworks Biotech Co., Ltd. · Updated on 2024-03-15

154

Participants Needed

1

Research Sites

108 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of MBS314, a new asymmetric trivalent tri-specific humanized antibody, in people with relapsed or refractory multiple myeloma. This Phase III, multicenter, open-label study is the first time this drug is being tested in humans and is sponsored by Beijing Mabworks Biotech Co., Ltd. The study is divided into two parts a dose escalation phase Phase Ia and an expansion phase Phase IbII. During Phase Ia, participants will receive MBS314 in one of seven different dose groups ranging from 0.03 mg to 60 mg, given by intravenous infusion according to the assigned schedule. Based on the results from this phase, one or two doses will be chosen for the Phase IbII part, where the recommended Phase II dose RP2D will be selected. The treatment involves receiving the study drug through IV infusions at specified doses and schedules. Participants will undergo assessments including monitoring for adverse events, dose-limiting toxicities, and determination of maximum tolerated dose. Efficacy will be evaluated by overall response rates and other measures such as complete response rates and minimal residual disease negativity over up to four years. Safety and tolerability will be followed for up to 29 months, with ongoing evaluations during the study. Participant involvement includes regular clinical visits for drug administration and detailed monitoring of health status and treatment effects throughout the study period.

CONDITIONS

Brief Title

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Research Team

L

Lugui Qiu, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here